Publication: Treatment endpoints for chronic hepatitis D
| dc.contributor.coauthor | Metin, Olga | |
| dc.contributor.department | School of Medicine | |
| dc.contributor.kuauthor | Yurtaydın, Süleyman Cihan | |
| dc.contributor.kuauthor | Zeybel, Müjdat | |
| dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
| dc.date.accessioned | 2024-11-10T00:02:42Z | |
| dc.description.abstract | Management of chronic hepatitis D (CHD) has entered a new era. In this new era, the virus entry inhibitor bulevirtide has received conditional approval as a treatment for compensated CHD. Three phase 3 studies with two new compounds are ongoing for the treatment of CHD. In this context, surrogate markers of treatment efficacy have been well defined for chronic hepatitis B (CHB) (7) and chronic hepatitis C (8) but not for CHD. The aim of this review is to give a perspective on treatment endpoints in CHD. For this, we took guidance from CHB studies and tried to make suggestions which differed according to finite versus prolonged treatment durations and also took into account the different characteristics of the new compounds. | |
| dc.description.indexedby | WOS | |
| dc.description.indexedby | Scopus | |
| dc.description.indexedby | PubMed | |
| dc.description.openaccess | NO | |
| dc.description.publisherscope | International | |
| dc.description.sponsoredbyTubitakEu | N/A | |
| dc.identifier.doi | 10.1111/liv.15447 | |
| dc.identifier.eissn | 1478-3231 | |
| dc.identifier.issn | 1478-3223 | |
| dc.identifier.scopus | 2-s2.0-85139790045 | |
| dc.identifier.uri | https://doi.org/10.1111/liv.15447 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14288/16169 | |
| dc.identifier.wos | 867490000001 | |
| dc.keywords | Chronic hepatitis D | |
| dc.keywords | Primary endpoints | |
| dc.keywords | Secondary endpoints | |
| dc.keywords | Treatment | |
| dc.language.iso | eng | |
| dc.publisher | Wiley | |
| dc.relation.ispartof | Liver International | |
| dc.subject | Gastroenterology | |
| dc.subject | Hepatology | |
| dc.title | Treatment endpoints for chronic hepatitis D | |
| dc.type | Review | |
| dspace.entity.type | Publication | |
| local.contributor.kuauthor | Zeybel, Müjdat | |
| local.contributor.kuauthor | Yurtaydın, Süleyman Cihan | |
| local.publication.orgunit1 | SCHOOL OF MEDICINE | |
| local.publication.orgunit2 | School of Medicine | |
| relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
| relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
| relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |